SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Poznan, Poland - 5 October 2024: GSK -Glaxosmithkline headquarters office building in Poznan.
Earnings
GSK to Inject ‘Tens of Billions’ in US Amid Trump’s Tariffs, Pipeline Reshuffles
CEO Emma Walmsley maintained that continued investment in the U.S. is a priority for the pharma to ensure its medicines for the country are supplied domestically.
July 30, 2025
 · 
2 min read
 · 
Tristan Manalac
businessman on dollar boat with storm and lightning
Business
Four Scrappy Biotechs Braving the Stormy Market Alone
Against steep odds and well-established paradigms, these four companies have successfully been commercializing their products on their own.
July 30, 2025
 · 
7 min read
 · 
Tristan Manalac
the businessman is watering money tree made by us dollar bills. Business, saving, growth, economic concept. Investors strategy, funding symbol. Copy space
Venture capital
The Top Five Biopharma Venture Capital Raises of H1, 2025
Though nerves abound for funders and founders in the industry, money continues to flow into startups, sometimes in eye-popping numbers. BioSpace rounds up the biggest raises so far this year.
July 30, 2025
 · 
3 min read
 · 
Dan Samorodnitsky
White and multi colored pills on white background top view
Opinion
IRA’s Definition of ‘Drug’ Creates Confusion for Developers
Under the Inflation Reduction Act, medications with the same active ingredient will be treated as the same drug for price negotiation purposes—even if approved by the FDA under a separate application—disincentivizing companies from investing time and money in gaining approval for new formulations and indications.
July 30, 2025
 · 
6 min read
 · 
T. Joseph Mattingly II
FDA
Prasad Out at CBER Following Sarepta Rollercoaster and Conservative Criticism
The FDA’s dramatic summer continues to unfold as news broke late Tuesday evening that Vinay Prasad will depart the agency, where he had been the head of the Center for Biologics Evaluation and Research for less than three months.
July 29, 2025
 · 
1 min read
 · 
Heather McKenzie
Facade of AstraZeneca's office in Shanghai, China
Earnings
AstraZeneca CEO Says World ‘Needs to Share’ in Global Pharma R&D
Pascal Soriot’s comments came during AstraZeneca’s Q2 earnings call in regard to President Donald Trump’s newly announced European pharma tariffs. The company also announced estimate-beating earnings, with its cancer portfolio driving earnings despite clinical roadblocks.
July 29, 2025
 · 
3 min read
 · 
Tristan Manalac
Creative collage picture human hands hold scissors banknote cash cut money inflation crisis funds salary devaluation drawing background.
Earnings
Merck Cuts $3B to Support Aggressive Launch Schedule, Late-Stage R&D
CEO Rob Davis referred to the cost reduction program as a ‘reallocation’ rather than a cut, with the savings to be reinvested to support up to 20 new product launches.
July 29, 2025
 · 
3 min read
 · 
Annalee Armstrong
Facade of Novo Nordisk's office in Fremont, California
C-suite
Novo Nordisk Names New Leader, Cuts 2025 Sales Guidance By 5%
In a surprise double announcement Tuesday, Novo reduced sales guidance by 5%—attributing the change to slowed growth of its semaglutide franchise in the U.S.—and named current international operations head Maziar Mike Doustdar as its new president and CEO.
July 29, 2025
 · 
2 min read
 · 
Heather McKenzie
External view of the U.S. Capitol building
Regulatory
Senate Democrats Investigating HHS Secretary Kennedy’s ACIP Firing
Six weeks after HHS Secretary RFK Jr. cited unexplained conflicts of interest in dismissing all 17 members of the CDC’s vaccine advisory committee, Democrats are asking for details.
July 29, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS